The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
36
No.
46
December 17, 2010
CCL
Vol.
33
No.
12
December 31, 2010
- Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma
- ASCO Calls On NCI To Double Funding For Cooperative Group Clinical Trials
- Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase
- Bosutinib Vs. Imatinib Study Didn’t Meet Primary Endpoint
- Autologous BMT Equivalent To Allogeneic For Myeloma
- Non-Adherence To Protocol Explains Outcome Differences In Hispanic Children With ALL
- Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study
- AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III
- Survival For ALL Increased To 94 Percent In Recent Years
- TTF Increased Survival Compared To Chemotherapy
- Randomized Trial Finds Sunscreen Use Cuts Risk Of Developing Melanoma
- Clinical Trials Approved By NCI CTEP Last Month